CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells

Immunology and Cell Biology

Volumn 88, Issue 5, 2010, Pages 565-574

  Yurchenko, Mariya Y ^a   Kovalevska, Larysa M ^a   Shlapatska, Larysa M ^a   Berdova, Ganna G ^a   Clark, Edward A ^b   Sidorenko, Svetlana P ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD150; Hodgkin's lymphoma; HPK1; JNK1 2

Indexed keywords

CD150 ANTIGEN; HEMATOPOIETIC PROGENITOR KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P54; PROTEIN SERINE THREONINE KINASE; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 9; STRESS ACTIVATED PROTEIN KINASE 1;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CELL LINE; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; NUCLEOTIDE SEQUENCE; PLASMA CELL; PROTEIN PHOSPHORYLATION; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SEPARATION; CYTOLOGY; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIGENS, CD; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SEPARATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77954315005     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.14     Document Type: Article

References (54)

1. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153-183.
2. Yasuda T, Sanjo H, Pages G, Kawano Y, Karasuyama H, Pouyssegur J et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 2008; 28: 499-508.
3. Turjanski AG, Vaque JP, Gutkind JS. MAP kinases and the control of nuclear events. Oncogene 2007; 26: 3240-3253.
4. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115: 61-70.
5. Graves JD, Draves KE, Craxton A, Saklatvala J, Krebs EG, Clark EA. Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. Proc Natl Acad Sci USA 1996; 93: 13814-13818.
6. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005; 106: 1382-1391.
7. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002; 32: 201-205.
8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
9. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 2003; 22: 8797-8801.
10. Alexaki VI, Javelaud D, Mauviel A. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 2008; 21: 429-438.
11. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118: 1853-1861.
12. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
13. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101: 1505-1512.
14. Packham G. The role of NF-kappaB in lymphoid malignancies. Br J Haematol 2008; 143: 3-15.
15. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-1027.
16. Mikhalap SV, Shlapatska LM, Yurchenko OV, Yurchenko MY, Berdova GG, Nichols KE et al. The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells. Blood 2004; 104: 4063-4070.
17. Mikhalap SV, Shlapatska LM, Berdova AG, Law CL, Clark EA, Sidorenko SP. CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 1999; 162: 5719-5727.
18. Nagy N, Cerboni C, Mattsson K, Maeda A, Gogolak P, Sumegi J et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer 2000; 88: 439-447.
19. Pinchouk VG, Sidorenko SP, Gluzman DF, Vetrova EP, Berdova AG, Schlapatskaya LN. Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens. Anticancer Res 1988; 8: 1377-1380.
20. Sidorenko SP, Clark EA. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 1993; 151: 4614-4624.
21. Sidorenko SP, Vetrova EP, Yurchenko OV, Berdova AG, Shlapatskaya LN, Gluzman DF. Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma 1992; 39: 3-9.
22. Punnonen J, Cocks BG, Carballido JM, Bennett B, Peterson D, Aversa G et al. Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med 1997; 185: 993-1004.
23. Yurchenko MY, Kashuba EV, Shlapatska LM, Sivkovich SA, Sidorenko SP. The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines. Exp Oncol 2005; 27: 24-30.
24. Dan I, Watanabe NM, Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol 2001; 11: 220-230.
25. Kiefer F, Tibbles LA, Anafi M, Janssen A, Zanke BW, Lassam N et al. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. EMBO J 1996; 15: 7013-7025.
26. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686.
27. Bartholdy B, Matthias P. Transcriptional control of B cell development and function. Gene 2004; 327: 1-23.
28. Dias S, Xu W, McGregor S, Kee B. Transcriptional regulation of lymphocyte development. Curr Opin Genet Dev 2008; 18: 441-448.
29. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
30. Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol 2003; 4: 19-24.
31. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergis-tically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001; 61: 5106-5115.
32. Lee Jr JT, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16: 486-507.
33. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851-859.
34. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
35. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
36. Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003; 25: 17-24.
37. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.
38. Bogoyevitch MA. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting. Bioessays 2006; 28: 923-934.
39. Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog 2007; 46: 591-598.
40. Li YY, Baccam M, Waters SB, Pessin JE, Bishop GA, Koretzky GA. CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. J Immunol 1996; 157: 1440-1447.
41. Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003; 111: 529-537. (Pubitemid 36228010)
42. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 2004; 1697: 89-101.
43. Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
44. Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol 2009; 30: 165-172.
45. Tibbles LA, Ing YL, Kiefer F, Chan J, Iscove N, Woodgett JR et al. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO J 1996; 15: 7026-7035.
46. Boomer JS, Tan TH. Functional interactions of HPK1 with adaptor proteins. J Cell Biochem 2005; 95: 34-44.
47. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762.
48. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128: 958-965.
49. Browning MB, Woodliff JE, Konkol MC, Pati NT, Ghosh S, Truitt RL et al. The T cell activation marker CD150 can be used to identify alloantigen-activated CD4(+)25+ regulatory T cells. Cell Immunol 2004; 227: 129-139.
50. Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995; 376: 260-263.
51. Romero X, Benitez D, March S, Vilella R, Miralpeix M, Engel P. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens 2004; 64: 132-144.
52. Mavaddat N, Mason DW, Atkinson PD, Evans EJ, Gilbert RJ, Stuart DI et al. Signaling lymphocytic activation molecule (CDw150) is homophilic but self-associates with very low affinity. J Biol Chem 2000; 275: 28100-28109.
53. Clark EA, Shu GL, Luscher B, Draves KE, Banchereau J, Ledbetter JA et al. Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol 1989; 143: 3873-3880.
54. Shlapatska LM, Mikhalap SV, Berdova AG, Zelensky OM, Yun TJ, Nichols KE et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 2001; 166: 5480-5487.